Overview

A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

Status:
Completed
Trial end date:
2017-06-07
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of ALKS 3831 in adult subjects with acute exacerbation of schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Alkermes, Inc.
Treatments:
Olanzapine